Topics

EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

13:43 EST 31 Jan 2020 | OncLive

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Original Article: EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

NEXT ARTICLE

More From BioPortfolio on "EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL"

Quick Search